WO2000068415A2 - A method for measuring biomolecules - Google Patents
A method for measuring biomolecules Download PDFInfo
- Publication number
- WO2000068415A2 WO2000068415A2 PCT/CA2000/000540 CA0000540W WO0068415A2 WO 2000068415 A2 WO2000068415 A2 WO 2000068415A2 CA 0000540 W CA0000540 W CA 0000540W WO 0068415 A2 WO0068415 A2 WO 0068415A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- label
- bioactive molecule
- vessel
- reactant
- sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
Definitions
- the present invention relates generally to the field of enzyme assays.
- a new assay method not only having potentially excellent sensitivity but being suitable for high throughput assays is preferable.
- This invention outlines a procedure that can achieve these goals.
- a method for measuring the activity or concentration of a bioactive molecule comprising: coating a reaction vessel with a reactant, said reactant being capable of interacting with a bioactive molecule having a biological activity; adding a sample to the reaction vessel, said sample comprising a known quantity of a detectable label and the bioactive molecule having the biological activity; incubating the reaction vessel under conditions wherein the reactant and the sample interact; removing a quantity of detectable label from the sample by binding detectable label to the reactant coated on the reaction vessel; transferring a soluble portion of the sample from the reaction vessel to a counting vessel ; and measuring the quantity of detectable label in the counting vessel.
- the detectable label may be selected from the group consisting of: enzyme label; colohmetric label; radioactive label; luminescent label and fluorescent label.
- the sample may be a biological sample.
- the biological activity may be an enzymatic activity or a binding affinity.
- the sample may include an inhibitor of the biological activity of the bioactive molecule or a competitor of the biological activity of the bioactive molecule.
- the bioactive molecule may be selected from the group consisting of: an enzymatic product; an enzyme; a substrate; a lectin; a lectin-binding ligand; a receptor; an inhibitor; a receptor binding ligand; an antigen; and an antibody.
- the compound may be selected from the group consisting of: an enzymatic product; an enzyme; a lectin; a lectin-binding ligand; a substrate; a receptor; an inhibitor; a receptor binding ligand; an antigen; and an antibody.
- a method for measuring the activity or concentration of a bioactive molecule comprising: coating a reaction vessel with a reactant, said reactant being capable of interacting with a bioactive molecule, said reactant including a detectable label; adding to the reaction vessel a sample, said sample including the bioactive molecule having a biological activity; releasing a quantity of detectable label from the reactant by incubating the reaction vessel under conditions such that the reactant and the detectable label contact the bioactive molecule and interact with the bioactive molecule; transferring a soluble portion of the sample containing released label from the reaction vessel to a counting vessel; and measuring the quantity of detectable label in the counting vessel.
- the detectable label may be selected from the group consisting of: enzyme label; colohmetric label; radioactive label; luminescent label; and fluorescent label.
- the sample may be a biological sample.
- the biological activity may be an enzymatic activity or a binding affinity.
- the sample may include an inhibitor of the biological activity of the bioactive molecule or a competitor of the biological activity of the bioactive molecule.
- the bioactive molecule may be selected from the group consisting of: an enzymatic product; an enzyme; a substrate; a receptor; a receptor ligand; an antigen; a lectin; a lectin-binding ligand; a ligand; and an antibody.
- Ligand refers to a bioactive molecule having specific binding affinity for another bioactive molecule.
- Receptor refers to a bioactive molecule that has a specific binding affinity for another bioactive molecule, for example, a ligand.
- Bioactive substance refers to a molecule or complex having a biological activity, for example, an enzymatic activity or binding
- the assay method is based on the principle of separating the reactants from the products after the completion of the reaction, followed by measurement of the amount of label transferred, as described below. It is important to note however that the method does not involve time-consuming separation steps, such as filtration or centhfugation, nor is it necessary to add reaction-stopping chemicals or agents, meaning that the method is ideally suited for high through-put assays.
- the method involves coating a reaction vessel with a reactant, identified hereafter as the coated reactant. Additional reactants are then added to the coated reaction vessel, forming a reaction mix. It is of note that as a result of this arrangement, the reaction mix has a bound portion (the coated reactant) and a soluble portion (the other reactants). Generally, the method is arranged such that either the coated reactant includes a label that will be released by the activity of the bioactive molecule or the soluble portion of the reaction mix includes a label which is bound to the coated reactant as a result of the activity of the bioactive molecule.
- label is either transferred from the bound portion of the reaction mix to the soluble portion of the reaction mix or from the soluble portion to the bound portion as a result of the activity of the bioactive molecule.
- the reaction is stopped by removing the soluble portion of the reaction mix from the coated reaction vessel and transferring the soluble reaction mix to a counting vessel, that is, an unused, untreated vessel, wherein the amount of label in the reaction mix is counted.
- the amount of the label in the counting vessel is either directly proportional to or reciprocally proportional to the activity or amount of the bioactive substrate, depending on the experimental design, as described below.
- the above-described method can be used to measure the activity of a variety of enzymes as well as the concentration of ligands within a sample, as described below.
- the method can also be used to measure the effect of various inhibitors on the activity of the enzymes and/or ligands.
- any suitable detectable label known in the art may be used, as described below. These include, but are by no means limited to, for example, colorimetric labels, radioactive labels, luminescent labels and fluorescent labels.
- the surface of the reaction vessel is coated with the coated reactant and the soluble portion of the reaction mix includes at least a bioactive molecule having a biological activity and a labeled substrate for the bioactive molecule.
- the substrate is labeled such that the activity of the bioactive molecule transfers the label from the substrate to the coated reactant, thereby producing labeled coated reactant. That is, the label is transferred from the soluble portion of the reaction mix to the bound portion of the reaction mix.
- the soluble portion of the reaction mix is removed from the coated reaction vessel, transferred to the counting vessel and counted. It is of note that the amount of label remaining in the soluble portion of the reaction mix is reciprocally proportional to the activity of the bioactive molecule.
- the activity of protein kinase A is assayed.
- the reaction vessel and the counting vessel are 96-well microplates are from VWR Canlab.
- other suitable vessels may also be used.
- hydrolyzed and partially dephosphorylated casein is dissolved in PBS to the concentration 5 ug/ml, and 100 ul/well is added to each well of the reaction vessel.
- the reaction vessel is then incubated at 37° C for 3 hr, and is then rinsed with PBST, producing a coated reaction vessel.
- the coated reaction vessel is coated with casein (the coated reactant).
- a series of concentrations of protein kinase A in phosphate buffer (PB pH 7.2, cAMP, 32 P-ATP) are then added to the wells of the coated reaction vessel (100 ul/well).
- the coated casien comprises the bound portion of the reaction mix
- the labeled ATP, protein kinase A and buffer comprise the soluble portion of the reaction mix and the bioactive molecule is protein kinase A.
- the reaction mixture is then incubation at 37° C for 30 min, during which time a quantity of the label, 32 P, is transferred from 32 P-ATP to casein by protein kinase A.
- the soluble portion of the reaction mix is transferred from each well of the coated reaction vessel to a corresponding well in the counting vessel, thereby stopping the reaction.
- the radioactivity of 32 P-ATP in the wells of the counting vessel are counted in a scintillation counter.
- the amount of label remaining in the soluble portion and transferred to the counting vessel is reciprocally proportional to the activity of the protein kinase A.
- the reaction may be carried out generally as described in Example I with the exception that the soluble portion of the reaction mix also includes an inhibitor of the activity of the bioactive molecule.
- the amount of label transferred to the counting vessel is directly proportional to the amount of inhibitor present in the reaction mix.
- the coated reaction vessel is prepared as described in Example I. Varying concentrations of a protein kinase A inhibitor, cAMP, in the phosphate buffer (PB pH 7.2, cAMP, 32 P-ATP) are added to the wells (50 ul/well) of the coated reaction vessel. Negative and positive control are also included. A pre-determined amount of protein kinase A (50 ul/well) is added to each well and the coated reaction vessel is incubated at 37° C for 30 min. The reaction is halted by removing the soluble portion of the reaction mix and transferring same to wells of the counting vessel.
- a protein kinase A inhibitor cAMP
- protein kinase A catalyzes the transfer of 32 P from 32 P-ATP to casein; however, in this example, cAMP inhibits the enzymatic activity of protein kinase A, meaning that the amount of label remaining in the soluble portion and transferred to the counting vessel is directly related to the concentration of the inhibitor.
- the reaction vessel is coated with a labeled coated reactant and the reaction mix includes at least a bioactive molecule having a biological activity.
- the coated reactant is labeled such that the activity of the bioactive molecule causes the label to be released from the coated reactant. That is, label is transferred from the bound portion of the reaction mix to the soluble portion of the reaction mix. After a set period of time, the soluble portion of the reaction mix is removed from the coated reaction vessel and transferred to the counting vessel.
- the amount of label present in the soluble portion of the reaction mix that is transferred to the counting vessel is directly proportional to the activity of the bioactive molecule.
- the activity of a variety of proteases is measured using a fluorescent label.
- the coated reaction vessel and the counting vessel are 96-well microplates are from VWR Canlab, although other suitable vessels may also be used.
- fluo-casein is prepared by mixing 5 mg NHS-coumarin in 100 ul DMSO with 10 mg casein in PBS (pH 7.2) in a micro-centrifuge tube. The tube is then incubated at room temperature for 3 hr. The fluo-casein (coated reactant) is then dissolved in PBS to the concentration 5 ug/ml and 100 ul/well is added to each well of the reaction vessel.
- the reaction vessel is incubated at 37° C for 3 hr, then rinsed with PBST, thereby producing a coated reaction vessel.
- a series of concentrations of a protease in a buffer (100 ul/well) is then added to the wells of the coated reaction vessel and the coated reaction vessel is incubated at 37° C or room temperature for 30 min.
- the fluo-casein is hydrolyzed by the protease, releasing the fluorescent label into the soluble portion of the reaction mix.
- the soluble portion of the reaction mix is then transferred from individual wells of the coated reaction vessel to corresponding wells of the counting vessel, thereby stopping the reaction.
- the fluorescent intensity of the label in each of the wells of the counting vessel is measured with a fluorometer.
- the amount of label in each well of the counting vessel is directly proportional to the activity of the protease.
- proteases include, but is by no means limited to, for example, proteinase K, elastase, protease XIII, papain, trypsin, pepsin and casein.
- the reaction may be carried out as described in Example III except that the soluble portion of the reaction mix also includes an inhibitor of the bioactive molecule.
- the amount of label transferred to the soluble portion and subsequently to the counting vessel is reciprocally proportional to the amount of inhibitor present in the reaction mix.
- the coated reaction vessel is prepared as described in Example III. Varying amounts of a protease inhibitor in the buffer (50 ul/well) are added to the wells of the coated reaction vessel. Negative and positive controls are included. A fixed concentration of the protease in buffer (50 ul/well) is added to the wells of the coated reaction vessel. The coated reaction vessel is incubated at 37° C or room temperature for 1 hr. The fluo-casein is cleaved by the protease, thereby releasing the fluorescent label into the soluble portion of the reaction mix; however, this cleavage is impeded by the inhibitor. Thus, the amount of label released into the soluble portion is reciprocally proportional to the degree of inhibition.
- the soluble portion of the reaction mix is transferred from each of the wells of the coated reaction vessel into corresponding wells of the counting vessel, thereby stopping the reaction.
- the fluorescent intensity of the label in the wells of the counting vessel is measured with a fluorometer and, as discussed above, is reciprocally proportional to the amount of inhibition of the protease activity.
- the reaction vessel is coated with a coated reactant which is a binding ligand for an enzymatic product, wherein the enzymatic product is formed by a bioactive molecule acting on at least a first substrate and a label.
- the activity of the bioactive molecule causes free label to be combined with the first substrate to form an enzymatic product.
- the enzymatic product then binds to the coated reactant and is removed from the soluble portion of the reaction mix. After a set period of time, the soluble portion of the reaction mix is removed from the coated reaction vessel and transferred to the counting vessel.
- the amount of label remaining in the soluble portion of the reaction mix is reciprocally proportional to the activity of the bioactive molecule.
- telomerase activity is measured. Specifically, Streptavidin or avidin (coated reactant) is dissolved in a buffer to a concentration of 5 ug/ml and 100 ul/well is added to each well of the reaction vessel. The reaction vessel is incubated at 37° C for 3 hr, and is then rinsed with PBST, thereby producing a coated reaction vessel. A series of concentrations of telomerase in a reaction mixture containing 50 mM Tris-acetate pH 8.5, 50 mM
- K acetate 5 mM ⁇ -mercaptoethanol, 1 mM spermidine, 1mM MgCI 2 ,
- Telomerase then elongates the primer, incorporating fluo-dGTP into the growing oligonucleotide chain. Unincorporated fluo-dGTP remains in the soluble portion of the reaction mixture and is transferred to the counting vessel.
- the fluorescent intensity of fluo-dGTP transferred into the counting vessel is measured with a fluorometer and is reciprocally proportional to the activity of telomerase.
- the telomerase reactions may be carried out in a separate vessel and then transferred to the coated reaction vessel.
- the telomerase reaction mix transferred to the coated reaction vessel will include both incorporated and unincorporated fluo-dGTP; however, the biotinylated primer will bind to the avidin or streptavidin, thereby removing the incorporated fluo-dGTP from the soluble portion of the reaction mix.
- the reaction may be carried out as described in Example V wherein the soluble portion of the reaction mix also includes an inhibitor of the bioactive molecule.
- the amount of label transferred to the counting vessel is directly proportional to the amount of inhibitor present in the reaction mix.
- the coated reaction vessel is prepared as described in Example V. Varying amounts of 7-deaza-dATP in reaction buffer (50 ul/well) are added to the wells of the coated reaction vessel. A fixed activity of telomerase in reaction buffer (50 ul/well) is added to the wells of the coated reaction vessel containing the inhibitor and the controls. The reaction vessel is then incubated at 30° C for 1-2 hr prior to stopping the DNA synthesis with the stop solution. As discussed above, the biotin primer binds to the streptavidin (avidin)- coated coated reaction vessel, meaning that incorporated label is removed from the soluble portion of the reaction mix, as discussed above.
- the soluble portion is then transferred to a counting vessel and the fluorescent intensity of fluo-dGTP is measured with a fluorometer and is directly proportional to the amount of the inhibitor. It is of note that, as discussed above, the telomerase reactions may be carried out in a separate reaction vessel first, as described above.
- the reaction vessel is coated with a coated reactant that has binding affinity for a substrate.
- Labeled substrate is prepared and is added to the coated reaction vessel along with unlabeled substrate.
- the labeled and unlabeled substrate may compete with one another for binding of the coated reactant or the coated reactant and the unlabeled substrate may compete with one another for binding to the labeled substrate.
- the amount of labeled substrate in the soluble portion of the reaction mix is directly proportional to the amount of unlabeled substrate.
- fluo-fimbriae is prepared by mixing 5 mg NHS-fluorescein in 100 ul DMSO with 10 mg fimbriae in 1 ml PBS (pH 7.2) followed by incubation at room temperature for 3 hr. The receptor is then dissolved in PBS (pH 7.2) to a concentration of 5 ug/ml and 100 ul/well is added to each well of the reaction vessel. The reaction vessel is incubated at 37° C for 3 hr, and is then rinsed with PBST, thereby forming a coated reaction vessel.
- a series of concentrations of the receptor in a buffer (50 ul/well) are added to the wells of the coated reaction vessel.
- a fixed amount of the fluo-fimbriae (50 ul/well) is added to each well containing the receptor and the control and incubated at 37° C for 1 hr.
- Competitive binding reactions between the immobilized receptor and the free receptor (competitor) to the fluo-fimbriae take place during incubation. That is, the fluo-fimbriae either binds to the immobilized receptor and is removed from the soluble portion or binds to the free receptor and remains in the soluble portion of the reaction mixture.
- the assay is stopped by removing the soluble portion of the reaction mixture and transferring same to the counting vessel.
- the fluorescent intensity of the fluo-fimbriae transferred into the wells of the counting vessel is determined using a fluorometer and is directly proportional to the amount of the receptor (competitor).
- a series of concentration of the fimbriae or E. coli cell in a buffer (50 ul/well) are added to the wells of a coated reaction vessel prepared as described above.
- a fixed amount of the fluo-fimbriae (50 ul/well) is added to each well containing the fimbriae or E. coli and control wells and incubated at 37° C for 1 hr.
- Competitive binding reactions between the fimbriae or E. coli (competitor) and the fluo-fimbriae to the immobilized receptor will occur, as described above.
- the assay is terminated by removing the soluble portion of the reaction mixture and transferring same to the counting vessel.
- the fluorescent intensity of the fluo-fimbriae transferred into the wells of the counting vessel is determined using a fluorometer and is directly proportional to the amount of the fimbriae or E. coli cells (competitor).
- the method is carried out as described above except that an inhibitor of binding is included.
- the amount of labeled substrate transferred to the counting vessel is directly proportional to the concentration of the inhibitor.
- the coated reaction vessel is prepared as described in Example VII.
- a series of concentration of the inhibitor in a buffer (50 ul/well) are added to the wells of the coated reaction vessel.
- a fixed amount of the fluo-fimbriae (50 ul/well) is added to each well containing the inhibitor and the controls and incubated at 37° C for 1 hr.
- the reactions between the inhibitor and the immobilized receptor for binding to fluo-fimbriae or between the inhibitor and the fluo-fimbriae for binding to the immobilized receptor will occur.
- the fluorescent intensity of the fluo-fimbriae transferred into the wells of the counting vessel is determined using a fluorometer and is directly proportional to the amount of the inhibitor (competitor).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00926619A EP1177443A2 (en) | 1999-05-10 | 2000-05-10 | A method for measuring biomolecules |
AU45317/00A AU4531700A (en) | 1999-05-10 | 2000-05-10 | A method for measuring biomolecules |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,270,639 | 1999-05-10 | ||
CA 2270639 CA2270639A1 (en) | 1999-05-10 | 1999-05-10 | A method for measuring biomolecules |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000068415A2 true WO2000068415A2 (en) | 2000-11-16 |
WO2000068415A3 WO2000068415A3 (en) | 2001-02-01 |
Family
ID=4163499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2000/000540 WO2000068415A2 (en) | 1999-05-10 | 2000-05-10 | A method for measuring biomolecules |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1177443A2 (en) |
AU (1) | AU4531700A (en) |
CA (1) | CA2270639A1 (en) |
WO (1) | WO2000068415A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017165665A1 (en) * | 2016-03-23 | 2017-09-28 | The General Hospital Corporation | Assays and methods for detecting udp-glucose |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296036A2 (en) * | 1987-06-15 | 1988-12-21 | Orgenics Ltd. | Reversed competitive solid phase immunoassay for detecting single epitope, analytes and kit therefor |
EP0308704A1 (en) * | 1987-09-03 | 1989-03-29 | Fuji Photo Film Co., Ltd. | Heterogeneous enzymimmunoassay |
EP0518557A2 (en) * | 1991-06-10 | 1992-12-16 | Eli Lilly And Company | Assay method for hydrolytic enzymes |
US5538858A (en) * | 1994-04-08 | 1996-07-23 | Pierce Chemical Company | Rapid assay for radioactive determination of protein kinase activity |
WO1997043438A1 (en) * | 1996-05-14 | 1997-11-20 | University Of Manitoba | Solid-phase activity assay for biologically active substance |
-
1999
- 1999-05-10 CA CA 2270639 patent/CA2270639A1/en not_active Abandoned
-
2000
- 2000-05-10 AU AU45317/00A patent/AU4531700A/en not_active Abandoned
- 2000-05-10 WO PCT/CA2000/000540 patent/WO2000068415A2/en active Search and Examination
- 2000-05-10 EP EP00926619A patent/EP1177443A2/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296036A2 (en) * | 1987-06-15 | 1988-12-21 | Orgenics Ltd. | Reversed competitive solid phase immunoassay for detecting single epitope, analytes and kit therefor |
EP0308704A1 (en) * | 1987-09-03 | 1989-03-29 | Fuji Photo Film Co., Ltd. | Heterogeneous enzymimmunoassay |
EP0518557A2 (en) * | 1991-06-10 | 1992-12-16 | Eli Lilly And Company | Assay method for hydrolytic enzymes |
US5538858A (en) * | 1994-04-08 | 1996-07-23 | Pierce Chemical Company | Rapid assay for radioactive determination of protein kinase activity |
WO1997043438A1 (en) * | 1996-05-14 | 1997-11-20 | University Of Manitoba | Solid-phase activity assay for biologically active substance |
Non-Patent Citations (2)
Title |
---|
JONES LAURIE J; UPSON ROSALYN H; HAUGLAND ROSARIA P; PANCHUK-VOLOSHINA NATALIYA; ZHOU MINGJIE; HAUGLAND RICHARD P: "Quenched BODIPY dye-labeled casein substrates for the assay of protease activity by direct fluorescence measurement" ANALYTICAL BIOCHEMISTRY, vol. 251, 1997, pages 144-152, XP002152059 cited in the application * |
TWINNING S S: "FLUORESCEIN ISOTHIOCYANATE-LABELED CASEIN ASSAY FOR PROTEOLYTIC ENZYMES" ANALYTICAL BIOCHEMISTRY, vol. 143, 1984, pages 30-34, XP000961435 cited in the application * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017165665A1 (en) * | 2016-03-23 | 2017-09-28 | The General Hospital Corporation | Assays and methods for detecting udp-glucose |
US11034992B2 (en) | 2016-03-23 | 2021-06-15 | The General Hospital Corporation | Assays and methods for detecting UDP-glucose |
Also Published As
Publication number | Publication date |
---|---|
WO2000068415A3 (en) | 2001-02-01 |
AU4531700A (en) | 2000-11-21 |
CA2270639A1 (en) | 2000-11-10 |
EP1177443A2 (en) | 2002-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3550358B2 (en) | Assays with extended dynamic range | |
Kolb et al. | Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence | |
US5328831A (en) | Substrate composition for solid phase urease immunoassay | |
EP0605430A1 (en) | Kit for liquid phase quantitative analysis of oligonucleotides and method of use thereof | |
CA2286414A1 (en) | Non-separation heterogenous assay for biological substance | |
Grandke et al. | Quality assurance in immunoassay performance-temperature effects | |
CN103443614A (en) | Use of signal enhancing compounds in electrochemiluminescence detection | |
EP3800474B1 (en) | Detection of multiple analytes | |
WO2006031815A2 (en) | Methods and compositions for proximity assays | |
CN101504410A (en) | Blood serum sample treatment preparation used for protein suspending chip detection | |
US20040043398A1 (en) | Use of the multipin platform as anchor device | |
CA2468275C (en) | Assaying apparatus, kit, and method for lipids and associated enzymes | |
US6030773A (en) | Chemiluminescent assay for DSDNA antibodies | |
JPH10511460A (en) | Time difference detection method for multiple analytes in test sample | |
EP1177443A2 (en) | A method for measuring biomolecules | |
WO1999054734A1 (en) | Comb-like solid phase for measuring analytes | |
EP0682254B1 (en) | Enzyme linked chemiluminescent assay | |
EP0943919B1 (en) | An assay surface that permits an analyte releasing step | |
JP2007516973A (en) | Metal ion mediated fluorescence superquenching assays, kits and reagents | |
US6251584B1 (en) | Specific binding assays using methyl orange | |
US7901901B2 (en) | Assays for measuring phosphate modification enzyme activity | |
CN117388499A (en) | Chemiluminescence protein chip method and kit for antigen proteins in serum | |
JP2003177131A (en) | Method for detecting biological bonding affinity | |
JPH0431763A (en) | Fluorometric analysis method using modified chelator | |
US20080274448A1 (en) | Method for detecting a hydrophobic region of a target substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000926619 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000926619 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10009891 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000926619 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |